LONDON, UK I June 02, 2025 I GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for ...

New drug application submission was based on positive data from the Phase III GLISTEN trial, which demonstrated significant ...

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ...

US FDA accepts for review GSK’s NDA for linerixibat to treat cholestatic pruritus in patients with PBC: London, UK Tuesday, June 3, 2025, 11:00 Hrs [IST] GSK plc announced the U ...

Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments.

A man’s acquired hemophilia coincided with a rare liver disease, a connection that had not been reported before, per a case ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has resumed the inclusion of patients to the clinical phase 1b/2a trial evaluating the ...

Liver disease is on the rise in the United States. Women are at a higher risk of developing a certain type of liver disease ...

This major step unlocks a new milestone payment of €26.5 million under our Licensing and Collaboration Agreement with Ipsen 2, due upon pricing and reimbursement of Iqirvo® (el ...

The presence of lymphoma can worsen liver damage in PBC and significantly accelerate the progression of liver disease.